Mitochondrial toxins in basal ganglia disorders: From animal models to therapeutic strategies

Current Neuropharmacology

Volumn 4, Issue 1, 2006, Pages 69-75

  Bonsi, Pisani ^a   Cuomo, D ^a,b   Martella, G ^b   Sciamanna, G ^a   Tolu, M ^b   Calabresi, P ^c   Bernardi, G ^a,b   Pisani, A ^a,b  

^a EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Huntington's disease; Parkinson's disease; Progressive supranuclear palsy; Striatum; Vulnerability

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTICONVULSIVE AGENT; ANTIOXIDANT; CASPASE INHIBITOR; LEVODOPA; MALONIC ACID; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE; ROTENONE; SUCCINATE DEHYDROGENASE; UBIDECARENONE;

CAUDATE NUCLEUS; CELL DEATH; CHOLINERGIC TRANSMISSION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DYSKINESIA; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME LOCALIZATION; EXTRAPYRAMIDAL SYNDROME; HUMAN; HUNTINGTON CHOREA; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; NERVE CELL; NERVE CELL PLASTICITY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; REVIEW; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA;

EID: 33646117989     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015906775203039     Document Type: Review

References (84)

1. Albers, D.S., Beal, M.F. (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural Transm. Suppl., 59, 133-154.
2. Beal, M.F. (2000) Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci., 23, 298-304.
3. Beister, A., Kraus, P., Kuhn, W., Dose, M., Weindl, A., Gerlach, M. (2004) The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J. Neural Transm. Suppl., 68, 117-22
4. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V., Greenamyre, J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 3, 1301-1306.
5. Bonsi, P., Calabresi, P., De Persis, C., Papa, M., Centonze, D., Bernardi, G., Pisani, A. (2004) Early ionic and membrane potential changes ceused by the pesticide rotenone in striatal cholinergic interneurons. Exp. Neurol., 185, 169-181.
6. Breysse, N., Amalric, M., Salin, P. (2003) Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J. Neurosci., 23, 8302-8309.
7. Breysse, N., Baunez, C., Spooren, W., Gasparini, F., Amalric, M. (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism J. Neurosci., 22, 5669-5678.
8. Brotchie, J.M., Lee, J., Venderova, K. (2005) Levodopa-induced dyskinesia in Parkinson's disease. J. Neural Transm., 112, 359-391.
9. Brouillet, E., Conde, F., Beal, M.F., Hantraye, P. (1999) Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol., 59, 427-468.
10. Brouillet, E., Hantraye, P. (1995) Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr. Opin. Neurol., 8, 469-473.
11. Browne, S.E., Beal, M.F. (2002) Toxin-induced mitochondrial dysfunction. Int.I Rev. Neurobiol., 53, 243-279.
12. Browne, S.E., Beal, M.F. (2004) The energetics of Huntington's disease. Neurochem. Res., 29, 531-546.
13. Burns, R.S., Chiueh, C.C., Markey, S.P., Ebert, M.H., Jacobowitz, D.M., Kopin, I.J. (1983) A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine.Proc. Natl. Acad Sci. USA, 80, 4546-50
14. Calabresi, P., Centonze, D., Bernardi, G. (2000) Electrophysiology of dopamine in normal and denervated striatal neurons. Trends Neurosci., 23, S57-S63.
15. Calabresi, P., Gubellini, P., Picconi, B., Centonze, D., Pisani, A., Bonsi, P., Greengard, P., Hipskind, R.A., Borrelli, E., Bernardi, G. (2001) Inhibition of mitochondrial complex II induces a long-term potentiation of NMDA-mediated synaptic excitation in the striatum requiring endogenous dopamine. J. Neurosci., 21, 5110-5120.
16. Calabresi, P., Mercuri, N.B., Sancesario, G., Bernardi, G. (1993) Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain, 116, 433-452.
17. Cattaneo, E., Calabresi, P. (2002) Mutant huntingtin goes straight to the heart. Nat. Neurosci., 5, 711-712.
18. Cenci, M.A., Whishaw, I.Q., Schallert, T. (2002) Animal models of neurological deficits: how relevant is the rat? Nat. Rev. Neurosci., 3, 574-579.
19. Champy, P., Hoglinger, G.U., Feger, J., Gleye, C., Hocquemiller, R., Laurens, A.,Guerineau, V., Laprevote, O., Medja, F., Lombes, A., Michel, P.P., Lannuzel, A., Hirsch, E.C., Ruberg, M. (2004) Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe. J. Neurochem., 88, 63-69.
20. Cicchetti, F., Prensa, L., Wu, Y., Parent, A. (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res. Brain Res. Rev., 34, 80-101.
21. Dunah, A.W., Wang, Y., Yasuda, R.P., Kameyama, K., Huganir, R.L., Wolfe, B.B., Standaert, D.G. (2000) Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol., 57, 342-352.
22. Ferrante, R.J., Gutekunst, C.A., Persichetti, F., McNeil, S.M., Kowall, N.W., Gusella, J.F., MacDonald, M.E., Beal, M.F., Hersch, S.M. (1997) Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci., 17, 3052-3063.
23. Fornai, F., Lenzi, P., Gesi, M., Ferrucci, M., Lazzeri, G., Busceti, C.L., Ruffoli, R., Soldani, P., Ruggieri, S., Alessandri, M.G., Paparelli, A. (2003) Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition. J. Neurosci., 23, 8955-8966.
24. Fornai, F., Schluter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C.L., Pontarelli, F., Battaglia, G., Pellegrini, A., Nicoletti, F., Ruggieri, S., Paparelli, A., Sudhof, T.C. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. USA, 102, 3413-3418.
25. Forno, LS., DeLanney, LE., Irwin, I., Langston, JW. (1993) Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Adv. Neurol., 60, 600-8.
26. Glinka, Y., Gassen, M., Youdim, M.B.H. (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J. Neural Transm., 50, 55-66.
27. Graybiel, A.M, Aosaki, T., Flaherty, A.W., Kimura, M. (1994) The basal ganglia and adaptive motor control. Science, 265, 1826-1831.
28. Green, D.R., Kroemer, G. (2004) The pathophysiology of mitochondrial cell death. Science, 305, 626-629.
29. Grondin, R., Zhang, Z, Ai, Y., Gash, D.M., Gerhardt, G.A. (2003) Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Prog. Drug Res., 61,101-23
30. Gunawardena, S., and Goldstein, L.S.B. (2005) Polyglutamine diseases and transport problems: deadly traffic jam on neuronal highways. Arch. Neurol., 62, 46-51.
31. Hallett, P.J., Standaert, D.G. (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther., 102, 155-174.
32. Hefti, F., Melamed, E., Wurtman, R.J. (1980) Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res., 195, 123-137.
33. Höglinger, G.U., Feger, J., Prigent, A., Michel, P.P., Parain, K., Champy, P., Ruberg, M., Oertel, W.H., Hirsch, E.C. (2003) Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem., 84, 491-502.
34. Jenner, P. (2003) The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology, 61(S3), S4-S11.
35. +: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase. Free Radic. Biol. Med, 15, 169-179.
36. Kopin, I.J. (1987) MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. Environ. Health Perspect., 75, 45-51.
37. Kume, A., Takahashi, A., Hashizume, Y. (1993) Neuronal cell los of the striatonigral system in multiple system atrophy. J Neurol. Sci., 117, 33-40.
38. Langston, J.W., Ballard, P., Tetrud, J.W., Irwin, I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 219, 979-980.
39. Lapointe, N., St-Hilaire, M., Martinoli, M.G., Blanchet, J., Gould, P., Rouillard, C., Cicchetti, F. (2004) Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J., 18, 717-719.
40. LeWitt, P.A. (2004) Clinical trials of neuroprotection for Parkinson's disease. Neurology, 63, S23-S31.
41. Liu, Y., Roghani, A., Edwards, R.H. (1992) Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenyl-pyridinium. Proc. Natl. Acad. Sci. USA, 89, 9074-9078.
42. Ludolph, A.C., He, F., Spencer, P.S., Hammerstad, J., Sabri, M. (1991) Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Cnd. J. Neurol. Sci., 18, 492-498.
43. Luthman, J., Fredriksson, A., Sundstrom, E., Jonsson, G., Archer, T. (1989) Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behaviour and monoamine alterations at adult stage. Behav. Brain Res., 33, 267-277.
44. Mandir, A.S., Przedborski, S., Jackson-Lewis, V., Wang, Z.-Q., Simbulan-Rosenthal, C.M., Smulson, M.E., Hoffman, B.E., Guastella, D.B., Dawson, V.L., Dawson, T.M. (1999) Poly(ADP-ribose) polymerase activation mediates 1-methyl 1-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism, Proc. Natl. Acad. Sci. USA, 96, 5774-5779.
45. McNaught, K.S., Olanow, C.W., Halliwell, B., Isacson, O., Jenner, P. (2001) Failure of the ubiquitin-proteasome system in Parkinson's disease, Nat. Rev. Neurosci., 2, 589-594.
46. Moratalla, R., Quinn, B., DeLanney, L.E., Irwin, L, Langston, J.W., Graybiel, A.M. (1992) Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA, 89, 3859-3863.
47. Murray, T.K., Messenger, M.J., Ward, M.A., Woodhouse, S., Osborne, D.J., Duty, S., O'Neill, M.J. (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol. Biochem. Behav., 73, 455-466.
48. Nicholls, D.G., Budd, S.L. (2000) Mitochondria and neuronal survival. Physiol. Rev., 80, 315-360.
49. Palfi, S., Ferrante, R.J., Brouillet, E., Beal, M.F., Dolan, R., Guyot, M.C., Peschanski, M., Hantraye, P. (1996) Chronic 3- nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci., 16, 3019-3025.
50. Perese, D.A., Ulman, J., Viola, J., Ewing, S.E., Bankiewicz, K.S. (1989) A 6-hyroxydopamine-induced selective parkinsonian rat model. Brain Res., 494, 285-293.
51. Périer, C., Agid, Y., Hirsch, E.C., Feger, J. (2000) Ipsilateral and contralateral subthalamic activity after unilateral dopaminergic lesion. Neuroreport, 11, 3275-3278.
52. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M.A., Calabresi, P. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci., 6, 501-506.
53. Picconi, B., Centonze, D., Rossi, S., Bernardi, G., Calabresi, P. (2004) Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism. Brain, 127, 1661-1669.
54. Pisani, A., Bonsi, P., Centonze, D., Gubellini, P., Bernardi, G., Calabresi, P. (2003) Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology, 45, 45-56.
55. Przdeborski, S., Vila, M. (2003) The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N.Y. Acad. Sci., 991, 189-198.
56. Pulsinelli, W.A. (1985) Selective neuronal vulnerability: morphological and molecular characteristics. Prog. Brain Res., 63, 29-37.
57. Ramsay, R.R., and Singer, T.P. (1986) Energy-dependent uptake of N-methyl-4-phenyl-pyridinium, the neurotoxic metabolite of 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria. J Biol. Chem., 261, 7585-7587.
58. Reddy, P.H., Williams, M., Tangle, D.A. (1999) Recent advances in understanding the pathogenesis of Huntington's disease. Trends Neurosci., 22, 248-255.
59. Rideout, H.J., Lang-Rollin, I.C.J., Savalle, M., Stefanis, L. (2005) Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J. Neurochem., 93, 1304-1313.
60. Ruberg, M., Javoy-Agid, F., Hirsch, E., Scatton, B., LHeureux, R., Hauw, J.-J., Duyckaerts, C., Gray, F., Morel-Maroger, A., Rascol, A., Serdaru, M., Agid, Y. (1985) Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann. Neurol., 18, 523-529.
61. Sachs, C., Jonsson, G. (1975) Mechanisms of action of 6-hydroxydopamine. Biochem. Pharmacol., 24, 1-8.
62. Salin, P., Hajji, M.D., Kerkerian-le Goff, L. (1996) Bilateral 6-hydroxydopamine-induced lesion of the nigrostriatal dopamine pathway reproduces the effects of unilateral lesion on substance P but not on enkephalin expression in rat basal ganglia. Eur. J. Neurosci., 8, 1746-1757.
63. Saulle, E., Gubellini, P., Picconi, B., Centone, D., Tropepi, D., Pisani, A., Morari, M., Marti, M., Rossi, L., Papa, M., Bernardi, G., Calabresi, P. (2004) Neuronal vulnerabilità following inhibition of mitochondrial complex II: a possibile ionic mechanism for Huntington's disease. Mol. Cell. Neurosci., 25, 9-20.
64. Schapira, A.H., Cooper, J.M., Dexter, D., Clark, J.B., Jenner, P., Marsden, C.D. (1990) Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem., 54, 823-827.
65. Scherfler, C., Puschban, Z., Ghorayeb, I., Goebel, G.P., Tison, F., Jellinger, K., Poewe, W., Wenning, G.K. (2000) Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy).Neuroscience, 99, 43-54.
66. Schiefer, J., Sprunken, A., Puls, C., Luesse, H.G., Milkereit, A., Milkereit, E., Johann, V., Kosinski, C.M. (2004) The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res., 1019, 246-254.
67. Schwarting, R.K.W., Huston, J.P. (1996) Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae. Prog. Neurobiol., 49, 215-266.
68. Sherer, T.B., Kim, J.H., Betarbet, R., Greenamyre, J.T. (2003) Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol., 179, 9-16.
69. Shults, C.W. (2005) Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol. Ther., 107, 120-130.
70. Sirinathsinghji, D.J., Kupsch, A., Mayer, E., Zivin, M., Pufal, D., Oertel, WH. (1992) Cellular localization of tyrosine hydroxylase mRNA and cholecystokinin mRNA-containing cells in the ventral mesencephalon of the common marmoset: effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. Mol. Brain Res., 12, 267-74.
71. Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L., Goedert, M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett., 251, 205-208.
72. Stefanova, N., Lundblad, M., Tison, F., Poewe, W., Cenci, M.A., Wenning, GK. (2004) Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). Neurobiol. Dis., 15, 630-9.
73. Suzuki, M., Desmond, T.J., Albin, R.L., Frey, K.A. (2002) Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology, 58, 1013-1018.
74. Swerdlow, R.H., Golbe, L.I., Parks, J.K., Cassarino, D.S., Binder, A.E., Grawey, A.E., Litvan, I., Bennett, J.P., Wooten, G.F., Parker, W.D. (2000) Mitochondrial dysfunction in cybrid lines expressing mitochondrial genes from patients with PSP. J. Neurochem., 75, 1681-1684.
75. Tretter, L., Sipos, I., Adam-Vizi, V. (2004) Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem. Res., 29, 569-577.
76. Ungerstedt, U. (1968) 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol., 5, 107-110.
77. Ungerstedt, U., Arbuthnott, G. (1970) Quantitative recording of rotational behaviour in rats after 6-hyroxydopamine lesions of the nigrostriatal dopamine system. Brain Res., 24, 485-493.
78. Varastet, M., Riche, D., Maziere, M., Hantraye, P. (1994) Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience, 63, 47-56
79. Vonsattel, J.P., DiFiglia, M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol., 57, 369-384.
80. Warren, N.M., Piggott, M.A., Perry, E.K., Burn, D.J. (2005) Cholinergic systems in progressive supranuclear palsy. Brain, 128, 239-249.
81. Wenning G.K., Granata, R., Laboyrie, P.M., Quinn, N.P., Jenner, P., Marsden, C.D. (1996) Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov. Disord, 11, 522-32.
82. Wenning, G.K., Colosimo, C., Geser, F., Poewe, W. (2004) Multiple system atrophy. Lancet Neurol., 3, 93-103.
83. White, J.K., Auerbach, W., Duyao, M.P., Vonsattel, J.P., Gusella, J.F., Joyner, A.L., MacDonald, M.E. (1997) Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat. Genet., 7, 404-410.
84. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W., Yankner, B.A (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med., 8, 600-606.